UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 59

Sortiert nach

Phase I/IIa, open-label, multicentre study to evaluate the optimal dosing and safety of ODM-203 in patients with advanced or metastatic solid tumours

ESMO open, 2020-12, Vol.5 (6), p.e001081, Article e001081

2020

Link zum Volltext

Verfügbarkeit prüfen

Interaction between the Amino- and Carboxyl-terminal Regions of the Rat Androgen Receptor Modulates Transcriptional Activity and Is Influenced by Nuclear Receptor Coactivators

The Journal of biological chemistry, 1997-11, Vol.272 (47), p.29821-29828

1997

Link zum Volltext

Verfügbarkeit prüfen

NMD and microRNA expression profiling of the HPCX1 locus reveal MAGEC1 as a candidate prostate cancer predisposition gene

BMC cancer, 2011-08, Vol.11 (1), p.327-327, Article 327

2011

Link zum Volltext

Verfügbarkeit prüfen

Lactase Persistence, Dietary Intake of Milk, and the Risk for Prostate Cancer in Sweden and Finland

Cancer epidemiology, biomarkers & prevention, 2007-05, Vol.16 (5), p.956-961

2007

Link zum Volltext

Verfügbarkeit prüfen

Real-world assessment of AR-LBD mutations in metastatic castration-resistant prostate cancer

Journal of clinical oncology, 2023-02, Vol.41 (6_suppl), p.204-204

2023

Link zum Volltext

Verfügbarkeit prüfen

Role of the Nijmegen Breakage Syndrome 1 Gene in Familial and Sporadic Prostate Cancer

Cancer epidemiology, biomarkers & prevention, 2006-05, Vol.15 (5), p.935-938

2006

Link zum Volltext

Verfügbarkeit prüfen

Germ-Line Alterations in MSR1 Gene and Prostate Cancer Risk

Clinical cancer research, 2003-11, Vol.9 (14), p.5252-5256

2003

Link zum Volltext

Verfügbarkeit prüfen

Mutual Transcriptional Interference between RelA and Androgen Receptor

The Journal of biological chemistry, 1996-09, Vol.271 (39), p.24151-24156

1996

Link zum Volltext

Verfügbarkeit prüfen

Impact of activating androgen receptor (AR) mutations on AR sensitivity to alternative ligands and response to ODM-208, a selective, first-in-class CYP11A1 inhibitor, in patients with advanced metastatic castration-resistant prostate cancer (mCRPC)

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.5057-5057

2022

Link zum Volltext

Verfügbarkeit prüfen

MK-5684 (ODM-208), a CYP11A1 inhibitor, in patients with metastatic castration-resistant prostate cancer (mCRPC) with and without AR-LBD mutations: CYPIDES phase 2 results

Journal of clinical oncology, 2024-02, Vol.42 (4_suppl), p.159-159

2024

Link zum Volltext

Verfügbarkeit prüfen

Phase 1 results of the ODM-208 first-in-human phase 1-2 trial in patients with metastatic castration-resistant prostate cancer (CYPIDES)

Journal of clinical oncology, 2022-02, Vol.40 (6_suppl), p.18-18

2022

Link zum Volltext

Verfügbarkeit prüfen

Association of E-Cadherin Germ-Line Alterations with Prostate Cancer

Clinical cancer research, 2001-11, Vol.7 (11), p.3465-3471

2001

Link zum Volltext

Verfügbarkeit prüfen

ODM-203, a Selective Inhibitor of FGFR and VEGFR, Shows Strong Antitumor Activity, and Induces Antitumor Immunity

Molecular cancer therapeutics, 2019-01, Vol.18 (1), p.28-38

2019

Link zum Volltext

Verfügbarkeit prüfen

Abstract 1753: Targeting cancer with selective cbp/p300 bromodomain inhibitors

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.1753-1753

2020

Link zum Volltext

Verfügbarkeit prüfen

Abstract 4649: ODM-207, a novel BET-bromodomain inhibitor as a therapeutic approach for the treatment of prostate and breast cancer

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.4649-4649

2016

Link zum Volltext

Verfügbarkeit prüfen

Abstract 118: Targeting cancer with a novel BET bromodomain inhibitor ODM-207

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.118-118

2017

Link zum Volltext

Verfügbarkeit prüfen

Targeted Inhibition of CYP11A1 in Castration-Resistant Prostate Cancer

NEJM evidence, 2024-01, Vol.3 (1), p.EVIDoa2300171

2024

Link zum Volltext

Verfügbarkeit prüfen

Structure-guided discovery of 1,3,5 tri-substituted benzenes as potent and selective matriptase inhibitors exhibiting in vivo antitumor efficacy

Bioorganic & medicinal chemistry, 2014-06, Vol.22 (12), p.3187-3203

2014

Link zum Volltext

Verfügbarkeit prüfen

Germline Alterations of the RNASEL Gene, a Candidate HPC1 Gene at 1q25, in Patients and Families with Prostate Cancer

American journal of human genetics, 2002-05, Vol.70 (5), p.1299-1304

2002

Link zum Volltext

Verfügbarkeit prüfen

A Combined Genomewide Linkage Scan of 1,233 Families for Prostate Cancer–Susceptibility Genes Conducted by the International Consortium for Prostate Cancer Genetics

American journal of human genetics, 2005-08, Vol.77 (2), p.219-229

2005

Link zum Volltext

Verfügbarkeit prüfen

Profiling genetic variation along the androgen biosynthesis and metabolism pathways implicates several single nucleotide polymorphisms and their combinations as prostate cancer risk factors

Cancer research (Chicago, Ill.), 2006-01, Vol.66 (2), p.743-747

2006

Link zum Volltext

Verfügbarkeit prüfen

Pooled genome linkage scan of aggressive prostate cancer : results from the International Consortium for Prostate Cancer Genetics

Human genetics, 2006-11, Vol.120 (4), p.471-485

SCHAID, Daniel J

2006

Link zum Volltext

Verfügbarkeit prüfen

ELAC2/HPC2 involvement in hereditary and sporadic prostate cancer

Cancer research (Chicago, Ill.), 2001-08, Vol.61 (16), p.6038-6041

2001

Link zum Volltext

Verfügbarkeit prüfen

Hemochromatosis gene mutations among Finnish male breast and prostate cancer patients

International journal of cancer, 2006-01, Vol.118 (2), p.518-520

2006

Link zum Volltext

Verfügbarkeit prüfen

KLF6 IVS1 -27G>A Variant and the Risk of Prostate Cancer in Finland

European urology, 2007-10, Vol.52 (4), p.1076-1081

2007

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 59

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(58)
Mit Volltextzugriff
(54)

Publikationsform

Artikel
(59)

Sprache

Englisch
(59)
Japanisch
(6)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Phase I/IIa, open-label, multicentre study to evaluate the optimal dosing and safety of ODM-203 in patients with advanced or metastatic solid tumours

Interaction between the Amino- and Carboxyl-terminal Regions of the Rat Androgen Receptor Modulates Transcriptional Activity and Is Influenced by Nuclear Receptor Coactivators

NMD and microRNA expression profiling of the HPCX1 locus reveal MAGEC1 as a candidate prostate cancer predisposition gene

Lactase Persistence, Dietary Intake of Milk, and the Risk for Prostate Cancer in Sweden and Finland

Real-world assessment of AR-LBD mutations in metastatic castration-resistant prostate cancer

Role of the Nijmegen Breakage Syndrome 1 Gene in Familial and Sporadic Prostate Cancer

Germ-Line Alterations in MSR1 Gene and Prostate Cancer Risk

Mutual Transcriptional Interference between RelA and Androgen Receptor

Impact of activating androgen receptor (AR) mutations on AR sensitivity to alternative ligands and response to ODM-208, a selective, first-in-class CYP11A1 inhibitor, in patients with advanced metastatic castration-resistant prostate cancer (mCRPC)

MK-5684 (ODM-208), a CYP11A1 inhibitor, in patients with metastatic castration-resistant prostate cancer (mCRPC) with and without AR-LBD mutations: CYPIDES phase 2 results

Phase 1 results of the ODM-208 first-in-human phase 1-2 trial in patients with metastatic castration-resistant prostate cancer (CYPIDES)

Association of E-Cadherin Germ-Line Alterations with Prostate Cancer

ODM-203, a Selective Inhibitor of FGFR and VEGFR, Shows Strong Antitumor Activity, and Induces Antitumor Immunity

Abstract 1753: Targeting cancer with selective cbp/p300 bromodomain inhibitors

Abstract 4649: ODM-207, a novel BET-bromodomain inhibitor as a therapeutic approach for the treatment of prostate and breast cancer

Abstract 118: Targeting cancer with a novel BET bromodomain inhibitor ODM-207

Targeted Inhibition of CYP11A1 in Castration-Resistant Prostate Cancer

Structure-guided discovery of 1,3,5 tri-substituted benzenes as potent and selective matriptase inhibitors exhibiting in vivo antitumor efficacy

Germline Alterations of the RNASEL Gene, a Candidate HPC1 Gene at 1q25, in Patients and Families with Prostate Cancer

A Combined Genomewide Linkage Scan of 1,233 Families for Prostate Cancer–Susceptibility Genes Conducted by the International Consortium for Prostate Cancer Genetics

Profiling genetic variation along the androgen biosynthesis and metabolism pathways implicates several single nucleotide polymorphisms and their combinations as prostate cancer risk factors

Pooled genome linkage scan of aggressive prostate cancer : results from the International Consortium for Prostate Cancer Genetics

ELAC2/HPC2 involvement in hereditary and sporadic prostate cancer

Hemochromatosis gene mutations among Finnish male breast and prostate cancer patients

KLF6 IVS1 -27G>A Variant and the Risk of Prostate Cancer in Finland

Suchergebnisse filtern